Pathology: laNSCLC - M - all population; mNSCLC - L1 - all population; mNSCLC - L1 - PDL1 positive; mNSCLC - L2 - PDL1 positive;
laNSCLC - M - all population | mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - PDL1 positive | ||
PACIFIC, 2017 | MYSTIC (D ; all population), 2020 | MYSTIC (D ; PDL1>25%), 2020 | ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 | ||
durvalumab alone | 4 | T1 | T1 | T1 | T1 |
Standard of Care (SoC) | 0 | T0 | T0 | T0 | |
placebo | 0 | T0 |